Cosalane and its analogues: A unique class of Anti-HIV agents

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 966-976

  Zhan, Peng ^a   Li, Zhenyu ^a   Liu, Xinyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

ADAMs; AIDS; CD4; Cosalane; gp120; HIV; Inhibitors; Non nucleoside RT inhibitors (NNRTIs); Reverse transcriptase (RT)

Indexed keywords

2 BENZOXAZOLONE DERIVATIVE; ALKENYLDIARYLMETHANE; ALPHA ANILINOPHENYLACETAMIDE; AMINO ACID DERIVATIVE; ANTIRETROVIRUS AGENT; ARYLSULFONYLBENZONITRILE; BENZENE DERIVATIVE; BENZOPHENONE; COLCHICINE; COSALANE; COSALANE DERIVATIVE; DIARYL ETHER; DIARYLMETHYLENEPIPERIDINE; ETHER DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDAZOLE DERIVATIVE; LIGNAN DERIVATIVE; LOVIRIDE; NEVIRAPINE; NITROIMIDAZOLE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PDE4B2; PIPERIDINE DERIVATIVE; TETRAHYDRONAPHTHALENE LIGNAN; TIBO AGENT; TUBULIN MODULATOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CRYSTAL STRUCTURE; CYTOTOXICITY; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHOBICITY; IC 50; NONHUMAN; PHARMACODYNAMICS; STRUCTURE ACTIVITY RELATION; VIRUS CULTURE; VIRUS REPLICATION; VIRUS STRAIN; X RAY CRYSTALLOGRAPHY;

ANTI-HIV AGENTS; ANTIGENS, CD4; AURINTRICARBOXYLIC ACID; HIV ENVELOPE PROTEIN GP120; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956705389     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710792007222     Document Type: Article

References (73)

1. AIDS Epidemic Update: December 2009. Joint United NationsProgramme on HIV/AIDS and World Health Organization 2009.
2. De Clercq, E. New approaches toward anti-HIV chemotherapy. J.Med. Chem., 2005, 48, 1297-313.
3. De Clercq, E. The history of antiretrovirals: key discoveries overthe past 25 years. Rev. Med. Virol., 2009, 19, 287-299.
4. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25years after the discovery of HIV. Int. J. Antimicrob. Agents, 2009,33, 307-320.
5. De Clercq, E. Highlights in the discovery of antiviral drugs: apersonal retrospective. J. Med. Chem., 2010, 53, 1438-1450.
6. Zhan, P.; Liu, X. Designed multiple ligands: an emerging anti-HIVdrug discovery paradigm. Curr. Pharm. Des., 2009, 15, 1893-1917.
7. Cushman, M.; Golebiewski, W.M.; McMahon, J.B.; Buckheit, R.W.Jr.; Clanton, D.J.; Weislow, O.; Haugwitz, R.D.; Bader, J.P.; Graham, L.; Rice, W.G. Design, synthesis, and biological evalua-tion of cosalane, a novel anti-HIV agent which inhibits multiplefeatures of virus reproduction. J. Med. Chem., 1994, 37, 3040-3050.
8. Myskiw, C.; Deschambault, Y.; Jefferies, K.; He, R.; Cao, J. Aurin-tricarboxylic acid inhibits the early stage of vaccinia virus replica-tion by targeting both cellular and viral factors. J. Virol., 2007, 81,3027-3032.
9. De Clercq, E. Potential antivirals and antiviral strategies againstSARS coronavirus infections. Expert Rev. Anti. Infect. Ther., 2006,4, 291-302.
10. Yap, Y.; Zhang, X.; Andonov, A.; He, R. Structural analysis ofinhibition mechanisms of aurintricarboxylic acid on SARS-CoVpolymerase and other proteins. Comput. Biol. Chem., 2005, 29,212-219.
11. He, R.; Adonov, A.; Traykova-Adonova, M.; Cao, J.; Cutts, T.; Grudesky, E.; Deschambaul, Y.; Berry, J.; Drebot, M.; Li, X. Po-tent and selective inhibition of SARS coronavirus replication byaurintricarboxylic acid. Biochem. Biophys. Res. Commun., 2004,320, 1199-1203.
12. Hung, H.C.; Tseng, C.P.; Yang, J.M.; Ju, Y.W.; Tseng, S.N.; Chen, Y.F.; Chao, Y.S.; Hsieh, H.P.; Shih, S.R.; Hsu, J.T. Aurintricar-boxylic acid inhibits influenza virus neuraminidase. Antiviral Res.,2009, 81, 123-131.
13. Kim, H.K.; Kim, J.E.; Park, C.M.; Kim, Y.T.; Han, K.S.; Cho, H.I.Aurintricarboxylic acid upregulates the thrombomodulin expres-sion of endothelial cells and peripheral blood monocytes. BloodCoagul. Fibrinolysis., 2008, 19, 489-494.
14. Sharma, R.K.; Chopra, S.; Sharma, S.D.; Pande, V.; Ramos, M.J.; Meguro, K.; Inoue, J.; Otsuka, M. Biological evaluation, chelation,and molecular modeling studies of novel metal-chelating inhibitorsof NF-kappaB-DNA binding: structure activity relationships. J.Med. Chem., 2006, 49, 3595-3601.
15. Sharma, R.K.; Garg, B.S.; Kurosaki, H.; Goto, M.; Otsuka, M.; Yamamoto, T.; Inoue, J. Aurine tricarboxylic acid, a potent metal-chelating inhibitor of NFkappaB-DNA binding. Bioorg. Med.Chem., 2000, 8, 1819-1823.
16. Ghosh, U.; Pandit, B.; Dutta, J.; Bhattacharyya, N.P. Induction ofapoptosis by benzamide and its inhibition by aurin tricarboxylicacid (ATA) in Chinese hamster V79 cells. Mutat. Res., 2004, 554,121-129.
17. Chen, C.W.; Chao, Y.; Chang, Y.H.; Hsu, M.J.; Lin, W.W.Inhibition of cytokine-induced JAK-STAT signalling pathways byan endonuclease inhibitor aurintricarboxylic acid. Br. J. Pharma-col., 2002, 137, 1011-1020.
18. Marchisio, M.; Grimley, P.M.; Di Baldassarre, A.; Santavenere, E.; Miscia, S. Novel shift of Jak/Stat signalling characterizes the pro-tective effect of aurintricarboxylic acid (ATA) from tumor necrosisfactor-alpha toxicity in human B lymphocytes. Int. J. Immunopa-thol. Pharmacol., 2004, 17, 5-14.
19. Andrew, D.J.; Hay, A.W.; Evans, S.W. Aurintricarboxylic acidinhibits apoptosis and supports proliferation in a haemopoieticgrowth-factor dependent myeloid cell line. Immunopharmacology,1999, 41, 1-10.
20. Kuchimanchi, K.R.; Udata, C.; Johnston, T.P.; Mitra, A.K.Pharmacokinetics, biliary excretion, and tissue distribution of novelanti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawleyrats. Drug Metab. Dispos., 2000, 28, 403-408.
21. Pal, D.; Udata, C.; Mitra, A.K. Transport of cosalane-a highlylipophilic novel anti-HIV agent-across caco-2 cell monolayers. J.Pharm. Sci., 2000, 89, 826-833.
22. Keyes, R.F.; Golebiewski, W.M.; Cushman, M. Correlation of anti-ing normal alkenyl and phosphodiester chains as cholestane re-placements. J. Med. Chem., 1996, 39, 508-514.
23. Golebiewski, W.M.; Keyes, R.F.; Cushman, M. Exploration of theeffects of linker chain modifications on anti-HIV activities in a se-ries of cosalane analogues. Bioorg. Med. Chem., 1996, 4, 1637-1648.
24. Udata, C.; Mitra, A.K.; Badr, M.Z. Disposition of cosalane, a novelanti-HIV agent, in isolated perfused rat livers. Drug Metab. Dis-pos., 1999, 27, 947-950.
25. De Clercq, E. The next ten stories on antiviral drug discovery (partE): Advents, Advances, and Adventures. Med. Res. Rev., 2009 Oct20. DOI 10.1002/med.20179.
26. Copeland, K.F. Inhibition of HIV-1 entry into cells.Recent Pat. Antiinfect. Drug Discov., 2006, 1, 107-112.
27. Strizki, J. Targeting HIV attachment and entry for therapy. AdvPharmacol., 2008, 56, 93-120.
28. Cushman, M.; Insaf, S.; Ruell, J.A.; Schaeffer, C.A.; Rice, W.G.Synthesis of a cosalane analog with an extended polyanionic phar-macophore conferring enhanced potency as an anti-HIV agent.Bioorg. Med. Chem. Lett., 1998, 8, 833-836.
29. Cushman, M.; Insaf, S.; Paul, G.; Ruell, J.A.; De Clercq, E.; Schols, D.; Pannecouque, C.; Witvrouw, M.; Schaeffer, C.A.; Turpin, J.A.; Williamson, K.; Rice, W.G. Extension of the polyan-ionic cosalane pharmacophore as a strategy for increasing anti-HIVpotency. J. Med. Chem., 1999, 42, 1767-1777.
30. Paul, G.C.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Loftus, T.L.; Turpin, J.A.; Buckheit, R.W.Jr.; Cushman, M. Identificationof optimal anion spacing for anti-HIV activity in a series ofcosalane tetracarboxylates. Bioorg. Med. Chem. Lett., 2000, 10,2149-2152.
31. Santhosh, K.C.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Loftus, T.L.; Turpin, J.A.; Buckheit, R.W.; Cushman, M. Anti-HIVactivity of a series of cosalane amino acid conjugates. Bioorg. Med.Chem. Lett., 2000, 10, 2505-2508.
32. Santhosh, K.C.; Paul, G.C.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Loftus, T.L.; Turpin, J.A.; Buckheit, R.W.Jr.; Cushman, M.Correlation of anti-HIV activity with anion spacingin a series of cosalane analogues with extended polycarboxylatepharmacophores. J. Med. Chem., 2001, 44, 703-714.
33. Kuchimanchi, K.R.; Gandhi, M.D.; Sheta, R.R.; Johnston, T.P.; Santhosh, K.C.; Cushman, M.; Mitra, A.K. Intestinal absorptionand biodistribution of cosalane and its amino acid conjugates:novel anti-HIV agents. Int. J. Pharm., 2002, 231, 197-211.
34. Casimiro-Garcia, A.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Loftus, T.L.; Turpin, J.A.; Buckheit, R.W.Jr.; Fanwick, P.E.; Cushman, M. Synthesis and anti-HIV activity of cosalane ana-logues incorporating two dichlorodisalicylmethane pharmacophorefragments. Bioorg. Med. Chem., 2001, 9, 2827-2841.
35. Casimiro-Garcia, A.; De Clercq, E.; Pannecouque, C.; Witvrouw, M.; Stup, T.L.; Turpin, J.A.; Buckheit, R.W.Jr.; Cushman, M.Synthesis and anti-HIV activity of cosalane analogues incorporat-ing nitrogen in the linker chain. Bioorg. Med. Chem., 2000, 8, 191-200.
36. Tronchet, J.M.; Seman, M. Nonnucleoside inhibitors of HIV-1reverse transcriptase: from the biology of reverse transcription tomolecular design. Curr. Top Med. Chem., 2003, 3, 1496-1511.
37. Martins, S.; Ramos, M.J.; Fernandes, P.A. The current status of theNNRTI family of antiretrovirals used in the HAART regimeagainst HIV infection. Curr. Med. Chem., 2008, 15, 1083-1095.
38. Zhou, Z.; Lin, X.; Madura, J.D. HIV-1 RT nonnucleoside inhibitorsand their interaction with RT for antiviral drug development. In-fect. Disord. Drug Targets, 2006, 6, 391-413.
39. Seminari, E.; Castagna, A.; Lazzarin, A. Etravirine for the treat-ment of HIV infection. Expert. Rev. Anti. Infect. Ther., 2008, 6,427-433.
40. Daar, E.S. Emerging resistance profiles of newly approved antiret-roviral drugs. Top HIV Med., 2008, 16, 110-116.
41. Zhan, P.; Liu, X.; Li, Z. Recent advances in the discovery anddevelopment of novel HIV-1 NNRTI platforms: 2006-2008 update.Curr. Med. Chem., 2009, 16, 2876-89.
42. Zhan, P.; Liu, X.; Li, Z.; Pannecouque, C.; De Clercq, E. Design strategies of novel NNRTIsto overcome drug resistance. Curr. Med. Chem., 2009, 16, 3903-3917.
43. Zhan, P.; Li, Z.; Liu, X.; De Clercq, E. Sulfanyltria-zole/tetrazoles: a promising class of HIV-1 NNRTIs. Mini. Rev.Med. Chem., 2009, 9, 1014-1023.
44. Cushman, M.; Golebiewski, W.M.; Graham, L.; Turpin, J.A.; Rice, W.G.; Fliakas-Boltz, V.; Buckheit, R.W.Jr. Synthesis and biologi-cal evaluation of certain alkenyldiarylmethanes as anti-HIV-1agents which act as non-nucleoside reverse transcriptase inhibitors.J. Med. Chem., 1996, 39, 3217-3227.
45. Cushman, M.; Casimiro-Garcia, A.; Hejchman, E.; Ruell, J.A.; Huang, M.; Schaeffer, C.A.; Williamson, K.; Rice, W.G.; Buckheit, R.W.Jr. New alkenyldiarylmethanes with enhanced potencies asanti-HIV agents which act as non-nucleoside reverse transcriptaseinhibitors. J. Med. Chem., 1998, 41, 2076-2089.
46. Cushman, M.; Casimiro-Garcia, A.; Williamson, K.; Rice, W.G.Synthesis of a non-nucleoside reverse transcriptase inhibitor in thealkenyldiarylmethane (ADAM) series with optimized potency andtherapeutic index. Bioorg. Med. Chem. Lett., 1998, 8, 195-198.
47. Casimiro-Garcia, A.; Micklatcher, M.; Turpin, J.A.; Stup, T.L.; Watson, K.; Buckheit, R.W.; Cushman, M. Novel modifications inthe alkenyldiarylmethane (ADAM) series of non-nucleoside re-verse transcriptase inhibitors. J. Med. Chem., 1999, 42, 4861-4874.
48. Xu, G.; Micklatcher, M.; Silvestri, M.A.; Hartman, T.L.; Burrier, J.; Osterling, M.C.; Wargo, H.; Turpin, J.A.; Buckheit, R.W.Jr.; Cushman, M. The biological effects of structural variation at themeta position of the aromatic rings and at the end of the alkenylchain in the alkenyldiarylmethane series of non-nucleoside reversetranscriptase inhibitors. J. Med. Chem., 2001, 44, 4092-4113.
49. Xu, G.; Loftus, T.L.; Wargo, H.; Turpin, J.A.; Buckheit, R.W.Jr.; Cushman, M. Solid-phase synthesis of the alkenyldiarylmethane(ADAM) series of non-nucleoside HIV-1 reverse transcriptase in-hibitors. J. Org. Chem., 2001, 66, 5958-5964.
50. Xu, G.; Hartman, T.L.; Wargo, H.; Turpin, J.A.; Buckheit, R.W.; Cushman, M. Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings. Bioorg. Med. Chem., 2002, 10, 283-290.
51. Silvestri, M.A.; Nagarajan, M.; De Clercq, E.; Pannecouque, C.; Cushman, M. Design, synthesis, anti-HIV activities, and metabolicstabilities of alkenyldiarylmethane (ADAM) non-nucleoside re-verse transcriptase inhibitors. J. Med. Chem., 2004, 47, 3149-3162.
52. Deng, B.L.; Hartman, T.L.; Buckheit, R.W.Jr.; Pannecouque, C.; De Clercq, E.; Fanwick, P.E.; Cushman, M. Synthesis, anti-HIVactivity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors. J. Med. Chem.,2005, 48, 6140-6155.
53. Deng, B.L.; Hartman, T.L.; Buckheit, R.W.Jr.; Pannecouque, C.; De Clercq, E.; Cushman, M. Replacement of the metabolically la-bile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxa-zole, oxazolone, or cyano substituents. J. Med. Chem., 2006, 49,5316-5323.
54. Sakamoto, T.; Cullen, M.D.; Hartman, T.L.; Watson, K.M.; Buck-heit, R.W.; Pannecouque, C.; De Clercq, E.; Cushman, M. Synthesis and anti-HIV activity of new metabolically stable alken-yldiarylmethane non-nucleoside reverse transcriptase inhibitors in-corporating N-methoxy imidoyl halide and 1,2,4-oxadiazole sys-tems. J. Med. Chem., 2007, 50, 3314-3321.
55. Cullen, M.D.; Deng, B.L.; Hartman, T.L.; Watson, K.M.; Buckheit, R.W.Jr.; Pannecouque, C.; De Clercq, E.; Cushman, M. Synthesisand biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increasedhydrolytic stability. J. Med. Chem., 2007, 50, 4854-4867.
56. Deng, B.L.; Zhao, Y.; Hartman, T.L.; Watson, K.; Buckheit, R.W.Jr.; Pannecouque, C.; De Clercq, E.; Cushman, M. Synthesisof alkenyldiarylmethanes (ADAMs) containing benzo [d]isoxazoleand oxazolidin-2-one rings, a new series of potent non-nucleosideHIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem., 2009,44, 1210-1214.
57. Deng, B.L.; Cullen, M.D.; Zhou, Z.; Hartman, T.L.; Buckheit, R.W.Jr.; Pannecouque, C.; De Clercq, E.; Fanwick, P.E.; Cushman, M. Synthesis and anti-HIV activity of new alkenyldiarylmethane(ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs)incorporating benzoxazolone and benzisoxazole rings. Bioorg MedChem., 2006, 14, 2366-2374.
58. Cullen, M.D.; Ho, W.C.; Bauman, J.D.; Das, K.; Arnold, E.; Hart-man, T.L.; Watson, K.M.; Buckheit, R.W.; Pannecouque, C.; DeClercq, E.; Cushman, M. Crystallographic study of a novel sub-nanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 re-verse transcriptase. J. Med. Chem., 2009, 52, 6467-6473.
59. Hara, H.; Fujihashi, T.; Sakata, T.; Kaji, A.; Kaji, H. Tetrahydron-aphthalene lignan compounds as potent anti-HIV type 1 agents.AIDS Res. Hum. Retroviruses, 1997, 13, 695-705.
60. Chan, J.H.; Hong, J.S.; Hunter, RN. 3rd.; Orr, G.F.; Cowan, J.R.; Sherman, D.B.; Sparks, S.M.; Reitter, B.E.; Andrews, CW 3rd.;Hazen, R.J.; St Clair, M.; Boone, L.R.; Ferris, R.G.; Creech, K.L.; Roberts, G.B.; Short, S.A.; Weaver, K.; Ott, R.J.; Ren, J.; Hopkins, A.; Stuart, D.I.; Stammers, D.K. 2-Amino-6-arylsulfonylbenzo-nitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.J. Med. Chem., 2001, 44, 1866-1882.
61. Jones, L.H.; Allan.; Barba, O.; Burt, C.; Corbau, R.; Dupont, T.; Kno chel, T.; Irving, S.; Middleton, D.S.; Mowbray, C.E.; Perros, M.; Ringrose, H.; Swain, N.A.; Webster, R.; Westby, M.; Phillips, C. Novel indazole non-nucleoside reverse transcriptase inhibitorsusing molecular hybridization based on crystallographic overlays.J. Med. Chem., 2009, 52, 1219-1223.
62. Wyatt, P.G.; Bethell, R.C.; Cammack, N.; Charon, D.; Dodic, N.; Dumaitre, B.; Evans, D.N.; Green, D.V.; Hopewell, P.L.; Humber, D.C.; et al. Benzophenone derivatives: a novel series of potent andselective inhibitors of human immunodeficiency virus type 1 re-verse transcriptase. J. Med. Chem. 1995, 38, 1657-1665.
63. Tucker, T.J.; Saggar, S.; Sisko, J.T.; Tynebor, R.M.; Williams, T.M.; Felock, P.J.; Flynn, J.A.; Lai, M.T.; Liang, Y.; McGaughey, G.; Liu, M.; Miller, M.; Moyer, G.; Munshi, V.; Perlow-Poehnelt, R.; Prasad, S.; Sanchez, R.; Torrent, M.; Vacca, J.P.; Wan, B.L.; Yan, Y. The design and synthesis of diaryl ether second generationHIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)with enhanced potency versus key clinical mutations. Bioorg. Med.Chem. Lett., 2008, 18, 2959-2966.
64. Silvestri, R.; Artico, M.; Massa, S.; Marceddu, T.; De Montis, F.;La Colla, P. 1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimida-zole: a potent lead for the design of novel NNRTIs. Bioorg. Med.Chem. Lett., 2000, 10, 253-256.
65. Duarte, C.D.; Barreiro, E.J.; Fraga, C.A. Privileged structures: auseful concept for the rational design of new lead drug candidates.Mini. Rev. Med. Chem., 2007, 7, 1108-1119.
66. DeSimone, R.W.; Currie, K.S.; Mitchell, S.A.; Darrow, J.W.; Pip-pin, D.A. Privileged structures: applications in drug discovery.Comb. Chem. High Throughput Screen, 2004, 7, 473-494.
67. Fischer, M.; Hubbard, R.E. Fragment-based ligand discovery. Mol.Interv., 2009, 9, 22-30.
68. Viegas-Junior, C.; Danuello, A.; da Silva Bolzani, V.; Barreiro, E.J.; Fraga, C.A. Molecular hybridization: a useful tool in the de-sign of new drug prototypes. Curr. Med. Chem., 2007, 14, 1829-1852.
69. Renner, S.; Schneider, G. Scaffold-hopping potential of ligand-based similarity concepts. ChemMedChem, 2006, 1, 181-185.
70. Xu, G.; Kannan, A.; Hartman, T.L.; Wargo, H.; Watson, K.; Turpin, J.A.; Buckheit, R.W.Jr.; Johnson, A.A.; Pommier, Y.; Cushman, M.Synthesis of substituted diarylmethylenepiperidines(DAMPs), a novel class of anti-HIV agents. Bioorg. Med. Chem.,2002, 10, 2807-2816.
71. Cullen, M.D.; Cheung, Y.F.; Houslay, M.D.; Hartman, T.L.; Wat-son, K.M.; Buckheit, R.W.Jr.; Pannecouque, C.; De Clercq, E.; Cushman, M. Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phos-phodiesterase-4B2 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18,1530-1533.
72. Cullen, M.D.; Sarkar, T.; Hamel, E.; Hartman, T.L.; Watson, K.M.; Buckheit, R.W.Jr.; Pannecouque, C.; De Clercq, E.; Cushman, M.Inhibition of tubulin polymerization by select alkenyldi-arylmethanes. Bioorg. Med. Chem. Lett., 2008, 18, 469-473.
73. Howard OM, Dong HF, Oppenheim JJ, Insaf S, Santhosh KC., Paul G., Cushman M. Inhibition of RANTES/CCR1-mediated chemo-taxis by cosalane and related compounds. Bioorg. Med. Chem.Lett., 2001, 11, 59-62.